Becton, Dickinson and Company (NYSE:BDX) Shares Purchased by Mcdaniel Terry & Co.

Mcdaniel Terry & Co. raised its holdings in Becton, Dickinson and Company (NYSE:BDX - Free Report) by 2.7% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 87,660 shares of the medical instruments supplier's stock after purchasing an additional 2,277 shares during the quarter. Becton, Dickinson and Company accounts for approximately 1.6% of Mcdaniel Terry & Co.'s investment portfolio, making the stock its 25th biggest holding. Mcdaniel Terry & Co.'s holdings in Becton, Dickinson and Company were worth $19,887,000 as of its most recent SEC filing.

A number of other institutional investors have also modified their holdings of the stock. Tompkins Financial Corp lifted its holdings in Becton, Dickinson and Company by 44.2% during the 3rd quarter. Tompkins Financial Corp now owns 150 shares of the medical instruments supplier's stock worth $36,000 after buying an additional 46 shares during the last quarter. Radnor Capital Management LLC increased its stake in Becton, Dickinson and Company by 1.7% in the third quarter. Radnor Capital Management LLC now owns 2,937 shares of the medical instruments supplier's stock valued at $708,000 after purchasing an additional 48 shares during the last quarter. Wesbanco Bank Inc. raised its holdings in Becton, Dickinson and Company by 1.9% during the fourth quarter. Wesbanco Bank Inc. now owns 2,558 shares of the medical instruments supplier's stock worth $580,000 after purchasing an additional 48 shares in the last quarter. Umpqua Bank boosted its holdings in shares of Becton, Dickinson and Company by 1.8% in the 3rd quarter. Umpqua Bank now owns 2,738 shares of the medical instruments supplier's stock valued at $660,000 after buying an additional 49 shares in the last quarter. Finally, Americana Partners LLC grew its position in shares of Becton, Dickinson and Company by 3.5% in the 3rd quarter. Americana Partners LLC now owns 1,468 shares of the medical instruments supplier's stock valued at $354,000 after buying an additional 50 shares during the last quarter. Hedge funds and other institutional investors own 86.97% of the company's stock.

Insider Activity at Becton, Dickinson and Company

In other Becton, Dickinson and Company news, EVP David Shan sold 500 shares of the firm's stock in a transaction on Tuesday, January 21st. The stock was sold at an average price of $240.00, for a total transaction of $120,000.00. Following the completion of the transaction, the executive vice president now owns 5,741 shares of the company's stock, valued at approximately $1,377,840. This trade represents a 8.01 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, EVP Michael David Garrison sold 597 shares of the company's stock in a transaction on Friday, January 17th. The shares were sold at an average price of $236.51, for a total value of $141,196.47. Following the completion of the sale, the executive vice president now owns 5,544 shares in the company, valued at $1,311,211.44. This represents a 9.72 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 10,544 shares of company stock valued at $2,370,309. Insiders own 0.36% of the company's stock.

Analysts Set New Price Targets

A number of equities research analysts recently weighed in on BDX shares. StockNews.com raised shares of Becton, Dickinson and Company from a "hold" rating to a "buy" rating in a research report on Wednesday, February 12th. Barclays boosted their target price on Becton, Dickinson and Company from $278.00 to $279.00 and gave the company an "overweight" rating in a report on Friday, February 14th. Finally, Piper Sandler raised their price target on Becton, Dickinson and Company from $275.00 to $280.00 and gave the stock an "overweight" rating in a research note on Tuesday, January 28th. Eight equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company presently has an average rating of "Buy" and an average target price of $278.29.

Becton, Dickinson and Company Price Performance

Shares of NYSE BDX traded down $0.39 during midday trading on Friday, hitting $227.54. The company had a trading volume of 834,158 shares, compared to its average volume of 2,052,694. The firm has a market capitalization of $65.34 billion, a price-to-earnings ratio of 37.80, a price-to-earnings-growth ratio of 1.63 and a beta of 0.40. Becton, Dickinson and Company has a twelve month low of $218.75 and a twelve month high of $251.99. The business has a 50-day simple moving average of $232.86 and a two-hundred day simple moving average of $233.34. The company has a quick ratio of 0.63, a current ratio of 1.13 and a debt-to-equity ratio of 0.69.

Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last announced its quarterly earnings results on Wednesday, February 5th. The medical instruments supplier reported $3.43 EPS for the quarter, topping the consensus estimate of $3.00 by $0.43. Becton, Dickinson and Company had a return on equity of 15.74% and a net margin of 8.47%. Equities research analysts anticipate that Becton, Dickinson and Company will post 14.43 earnings per share for the current year.

Becton, Dickinson and Company declared that its Board of Directors has authorized a stock buyback plan on Tuesday, January 28th that allows the company to repurchase 10,000,000 shares. This repurchase authorization allows the medical instruments supplier to repurchase shares of its stock through open market purchases. Stock repurchase plans are generally a sign that the company's board believes its stock is undervalued.

Becton, Dickinson and Company Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, March 31st. Investors of record on Monday, March 10th will be given a $1.04 dividend. The ex-dividend date of this dividend is Monday, March 10th. This represents a $4.16 annualized dividend and a dividend yield of 1.83%. Becton, Dickinson and Company's dividend payout ratio is presently 69.10%.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.